NM_000432.4:c.433G>A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 4P and 4B. PM1PP3_ModerateBS2
The NM_000432.4(MYL2):c.433G>A(p.Asp145Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000323 in 1,612,276 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000432.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL2 | NM_000432.4 | c.433G>A | p.Asp145Asn | missense_variant | Exon 7 of 7 | ENST00000228841.15 | NP_000423.2 | |
MYL2 | NM_001406745.1 | c.391G>A | p.Asp131Asn | missense_variant | Exon 6 of 6 | NP_001393674.1 | ||
MYL2 | NM_001406916.1 | c.376G>A | p.Asp126Asn | missense_variant | Exon 7 of 7 | NP_001393845.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYL2 | ENST00000228841.15 | c.433G>A | p.Asp145Asn | missense_variant | Exon 7 of 7 | 1 | NM_000432.4 | ENSP00000228841.8 | ||
MYL2 | ENST00000548438.1 | c.391G>A | p.Asp131Asn | missense_variant | Exon 6 of 6 | 3 | ENSP00000447154.1 | |||
MYL2 | ENST00000663220.1 | c.376G>A | p.Asp126Asn | missense_variant | Exon 7 of 7 | ENSP00000499568.1 |
Frequencies
GnomAD3 genomes AF: 0.0000463 AC: 7AN: 151142Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000201 AC: 5AN: 249004Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 134774
GnomAD4 exome AF: 0.0000308 AC: 45AN: 1461134Hom.: 0 Cov.: 31 AF XY: 0.0000344 AC XY: 25AN XY: 726870
GnomAD4 genome AF: 0.0000463 AC: 7AN: 151142Hom.: 0 Cov.: 31 AF XY: 0.0000271 AC XY: 2AN XY: 73670
ClinVar
Submissions by phenotype
not specified Uncertain:1
Variant summary: MYL2 c.433G>A (p.Asp145Asn) results in a conservative amino acid change located in the EF-hand domain (IPR002048) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 249004 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.433G>A has been reported in the literature in at least one individual affected with Hypertrophic Cardiomyopathy, reported as a VUS (example: Haskell_2017). These report(s) do not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 28611029, 35629155). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Hypertrophic cardiomyopathy 10 Uncertain:1
This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 145 of the MYL2 protein (p.Asp145Asn). This variant is present in population databases (rs199567559, gnomAD 0.004%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 28611029, 35629155). ClinVar contains an entry for this variant (Variation ID: 191733). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiomyopathy Uncertain:1
This missense variant replaces aspartic acid with asparagine at codon 145 of the MYL2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with hypertrophic cardiomyopathy (PMID: 28611029). This variant has been identified in 5/249004 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Arrhythmogenic right ventricular cardiomyopathy Uncertain:1
- -
not provided Uncertain:1
- -
Hypertrophic cardiomyopathy Uncertain:1
This missense variant replaces aspartic acid with asparagine at codon 145 of the MYL2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with hypertrophic cardiomyopathy (PMID: 28611029). This variant has been identified in 5/249004 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The p.D145N variant (also known as c.433G>A), located in coding exon 7 of the MYL2 gene, results from a G to A substitution at nucleotide position 433. The aspartic acid at codon 145 is replaced by asparagine, an amino acid with highly similar properties. This variant was identified in an individual with hypertrophic cardiomyopathy; howerver, clinical details were limited (Haskell GT et al. Circ Cardiovasc Genet, 2017 Jun;10). This variant was also reported as a secondary cardiac variant in an exome cohort (Ng D et al. Circ Cardiovasc Genet, 2013 Aug;6:337-46). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at